AUTHORS
David Aaron Russler-Germain, MD, PhD, Fei Wan, PhD2, Amalia Dubois3, Chaz Moreno4, Francesca Loyet5, Hunter Cassidy Cochran, MD6, Dilan Anil Patel, MD7, Brad S. Kahl, MD8, Todd Fehniger, MD, PhD9, Amanda Cashen, MD10, Armin Ghobadi, MD11, Neha Mehta-Shah, MD, MSCI12, Nancy L. Bartlett, MD13
AFFILIATIONS
1 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
8 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
9 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
10 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
11 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
12 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
13 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Background: For patients (pts) with LBCL relapsing >1 year after frontline therapy, standard treatment is platinum-based salvage chemotherapy and consolidative autologous stem cell transplant (ASCT). While chimeric antigen receptor T-cell (CART) therapy is typically preferred for patients with primary refractory/early relapsing LBCL, many pts need systemic therapy pre-apheresis given CART approval/production timelines. We hypothesized platinum-based salvage strategies may be improved by incorporating the novel agent mosunetuzumab (Mosun), a CD3xCD20 bispecific T-cell engager, instead of rituximab retreatment.
Methods: This single center, investigator-initiated phase 1b trial with expansion cohorts enrolled 24 pts with R/R LBCL after frontline rituximab + anthracycline-based chemotherapy (NCT05464329). All pts receive at least 2 cycles of concurrent Mosun + platinum-based chemotherapy, with chemotherapy per investigator (Arm A: dexamethasone, cytarabine, oxaliplatin [DHAX]; Arm B: ifosfamide, carboplatin, etoposide [ICE]). For all pts, Mosun was administered outpatient by IV infusion on 21-day cycles. In Cycle (C) 1, Mosun was given on Day (D) 1 (1mg), D8 (2mg), and D15 (60mg). In C2+, Mosun was given on D1 only (60mg for C2; 30mg for C3+). Pts received 20mg IV dexamethasone prior to each C1-C2 Mosun dose, with optional steroid premeds thereafter. DHAX/ICE were given per institutional standards. All pts undergo response assessment by FDG PET-CT post-C2 (PET2). Pts with interim complete response (CR) or adequate partial response (PR; determined by investigator) proceed to pre-specified consolidation per investigator (ASCT or CART) directly or after up to 2 optional additional cycles of Mosun + DHAX/ICE. The primary endpoint was safety; secondary endpoints included ORR, CRR, DOR, PFS, and OS.
Results: Between December 2022 and October 2025, the accrual target of 24 pts was met (Arm A [DHAX]: 12; Arm B [ICE]: 12). At data cutoff (July 27, 2026), median follow-up was 12.2 months (range: 3.8–33.2). Median age at study entry was 64 years (range: 47–73). All pts had received 1 prior line of therapy. Eleven pts had primary refractory/early relapsing LBCL. Four pts had double-hit lymphoma. One pt withdrew consent pre-C1D8 and was evaluable only for safety and survival but not DLTs or response. Median number of cycles received was 3 (1, n=1; 2, n=8; 3, n=14; 4, n=1). Twenty-three pts were evaluable for PET2 response, with an overall response rate (ORR) of 21/23 (91.3%) and complete response rate of 11/23 (47.8%). Seventeen patients proceeded to planned ASCT consolidation and 1 proceeded to planned CART consolidation. One patient planned for ASCT had inadequate PR and received third-line CART off-study. The other two responding patients experienced PD between initial response and planned consolidation. Median DOR, PFS, and OS have not been reached. Estimated 12-month DOR is 80.7% (95%CI: 56.3–92.3%), PFS is 66.7% (95%CI: 44.3–81.7%), and OS is 87.1% (95%CI: 65.2–95.7%).
CRS occurred in 45.8% of patients (gr1: 41.7%, gr2: 4.2%; no tocilizumab required). No AEs consistent with ICANS were reported. Serious AEs were gr1–2 CRS (n=5), gr2 confusion/psychosis (n=4; all attributed to steroids or ifosfamide neurotoxicity), gr3 cholecystitis (n=1), gr3 diverticulitis (n=1), gr3 lower GI bleed (n=1), gr3 nausea (n=1), gr3 thrombosis (n=1), gr2 infusion reaction (n=1; attributed to cytarabine), and gr2 RBC transfusion reaction (n=1). Mosun AEs of special interest were gr2 increased ALT (n=2), gr3 syncope (n=1), gr2 CRS (n=1), and gr2 increased bilirubin (n=1). Other notable AEs likely attributable to DHAX/ICE were gr3+ thrombocytopenia (n=16), gr3+ anemia (n=10), and gr3+ neutropenia (n=5). No febrile neutropenia was observed. No deaths occurred during study treatment initiation through 30 days after the last dose of study treatment. Four deaths have occurred: sepsis D+10 post-ASCT (n=1), respiratory failure due to metapneumovirus D+396 post-ASCT (n=1), HLH due to Ehrlichiosis D+173 post-ASCT (n=1), and refractory LBCL despite subsequent CART (n=1).
Conclusions: Mosun + DHAX/ICE demonstrated a safety and tolerability profile consistent with expectations, notable for low-grade CRS and few infectious complications. Efficacy results reveal promising anti-lymphoma activity in a high-risk population, with high ORR rate and durable responses after consolidation even for patients in PR going to ASCT. This regimen is encouraging for further study.
DISCLOSURES
David Aaron Russler-Germain, MD, PhD: Abbvie - Consultancy (Includes expert testimony); Tempus - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Natera - Consultancy (Includes expert testimony)